Sector
PharmaceuticalsCMP
as on 03 Jul, 2024 12:00:00 AM
Open
₹2,137.9Prev. Close
₹2,129.1Turnover(Lac.)
₹7,068.97Day's High
₹2,149.8Day's Low
₹2,116.3552 Week's High
₹2,49052 Week's Low
₹1,661.05Book Value
₹239.8Face Value
₹1Mkt Cap (₹ Cr.)
85,715.89P/E
46.99EPS
45.51Divi. Yield
024 Aug 2023
12:00 AM
AGM
Announcement Date: 24 Aug, 2023
8 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 40.06 | 40.06 | 40.06 | 40.06 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 7,743.85 | 6,500.39 | 4,694.21 | 3,611.39 |
Net Worth | 7,783.91 | 6,540.45 | 4,734.27 | 3,651.45 |
Minority Interest |
No Record found
No Record found
No Record found
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 10,334.77 | 8,749.43 | 7,781.56 | 6,214.43 | 5,865.23 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 10,334.77 | 8,749.43 | 7,781.56 | 6,214.43 | 5,865.23 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 296.07 | 140.99 | 210.48 | 182.63 | 121.96 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,521.95 | 120.29 | 3,65,682.64 | 867.6 | 0.89 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,560 | 76.97 | 1,21,312.5 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,476.55 | 32.36 | 1,20,195.02 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,092.45 | 31.35 | 1,08,114.81 | 1,405.2 | 0.28 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,491.9 | 24.48 | 1,06,298.05 | 1,034.8 | 0.63 | 5,081.8 | 1,453.02 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Wholetime Director
RAMESH CHAND JUNEJA
Vice Chairman & M.D.
RAJEEV JUNEJA
Whole Time Director & CEO
SHEETAL ARORA
Independent Director
TILOKCHAND PUNAMCHAND OSTWAL
Company Sec. & Compli. Officer
Pradeep Chugh
Independent Director
Bharat Anand
Whole-time Director
SATISH KUMAR SHARMA
Independent Director
Vivek Kalra
Independent Director
Vijaya Sampath
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Mankind Pharma Ltd
Summary
Mankind Pharma Ltd. was incorporated on July 3, 1991, as a Private Limited Company with the name Mankind Pharma Private Limited, by the Registrar of Companies, Delhi and Haryana, at New Delhi. Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to Mankind Pharma Limited and the RoC issued a fresh Certificate of Incorporation on April 13, 2006.The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products. It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory. In 2004, the Company entered the chronic pharmaceutical segment with the launch of Amlokind tablets and Glimestar tablets amongst others. It set up their first manufacturing facility at Paonta Sahib, in Himachal Pradesh during year 2005. It entered the ophthalmic pharmaceutical segment with the launching of Lubistar Eye Drops and Tobastar Eye Drops. In 2007, the Company entered the consumer healthcare segment with the launch of Manforce brand and have since established several differentiated brands in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineralsupplements and anti-acne preparations categories. It entered into the business of animal heal
Read More
What is the Mankind Pharma Ltd share price today?
The Mankind Pharma Ltd shares price on nse is Rs.₹2139.5 today.
What is the Market Cap of Mankind Pharma Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Mankind Pharma Ltd is ₹85715.89 Cr. as of 03 Jul ‘24
What is the PE and PB ratio of Mankind Pharma Ltd?
The PE and PB ratios of Mankind Pharma Ltd is 46.99 and 8.90 as of 03 Jul ‘24
What is the 52 Week High and Low of Mankind Pharma Ltd?
The 52-week high/low is the highest and lowest price at which a Mankind Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Mankind Pharma Ltd is ₹1661.05 and ₹2490 as of 03 Jul ‘24
What is the CAGR of Mankind Pharma Ltd?
Mankind Pharma Ltd's CAGR for 5 Years at N/I%, 3 Years at N/I%, 1 Year at 25.43%, 6 Month at 1.04%, 3 Month at -11.04% and 1 Month at 0.17%.
What is the shareholding pattern of Mankind Pharma Ltd?
The shareholding pattern of Mankind Pharma Ltd is as follows:
Promoters - 74.88 %
Institutions - 21.01 %
Public - 4.11 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
